These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

791 related items for PubMed ID: 22873657

  • 21. Clinical outcomes after treatment of non-contained intrabony defects with enamel matrix derivative or guided tissue regeneration: a 12-month randomized controlled clinical trial.
    Siciliano VI, Andreuccetti G, Siciliano AI, Blasi A, Sculean A, Salvi GE.
    J Periodontol; 2011 Jan; 82(1):62-71. PubMed ID: 20809859
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical evaluation of demineralized freeze-dried bone allograft with and without enamel matrix derivative for the treatment of periodontal osseous defects in humans.
    Hoidal MJ, Grimard BA, Mills MP, Schoolfield JD, Mellonig JT, Mealey BL.
    J Periodontol; 2008 Dec; 79(12):2273-80. PubMed ID: 19053917
    [Abstract] [Full Text] [Related]

  • 27. Treatment of intrabony defects with enamel matrix proteins or bioabsorbable membranes. A 4-year follow-up split-mouth study.
    Sculean A, Donos N, Miliauskaite A, Arweiler N, Brecx M.
    J Periodontol; 2001 Dec; 72(12):1695-701. PubMed ID: 11811505
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of EDTA root conditioning on the healing of intrabony defects treated with an enamel matrix protein derivative.
    Sculean A, Berakdar M, Willershausen B, Arweiler NB, Becker J, Schwarz F.
    J Periodontol; 2006 Jul; 77(7):1167-72. PubMed ID: 16805678
    [Abstract] [Full Text] [Related]

  • 30. Five-year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration.
    Sculean A, Donos N, Schwarz F, Becker J, Brecx M, Arweiler NB.
    J Clin Periodontol; 2004 Jul; 31(7):545-9. PubMed ID: 15191590
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Enamel matrix derivative versus bioactive ceramic filler in the treatment of intrabony defects: 12-month results.
    Leknes KN, Andersen KM, Bøe OE, Skavland RJ, Albandar JM.
    J Periodontol; 2009 Feb; 80(2):219-27. PubMed ID: 19186961
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study.
    Sculean A, Donos N, Blaes A, Lauermann M, Reich E, Brecx M.
    J Periodontol; 1999 Mar; 70(3):255-62. PubMed ID: 10225541
    [Abstract] [Full Text] [Related]

  • 39. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial.
    Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H, Rasperini G, Merli M, Cortellini P, Suvan JE.
    J Periodontol; 2004 May; 75(5):726-33. PubMed ID: 15212355
    [Abstract] [Full Text] [Related]

  • 40. Enamel matrix proteins in the regenerative therapy of deep intrabony defects.
    Tonetti MS, Lang NP, Cortellini P, Suvan JE, Adriaens P, Dubravec D, Fonzar A, Fourmousis I, Mayfield L, Rossi R, Silvestri M, Tiedemann C, Topoll H, Vangsted T, Wallkamm B.
    J Clin Periodontol; 2002 Apr; 29(4):317-25. PubMed ID: 11966929
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.